MX2019009772A - Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. - Google Patents

Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.

Info

Publication number
MX2019009772A
MX2019009772A MX2019009772A MX2019009772A MX2019009772A MX 2019009772 A MX2019009772 A MX 2019009772A MX 2019009772 A MX2019009772 A MX 2019009772A MX 2019009772 A MX2019009772 A MX 2019009772A MX 2019009772 A MX2019009772 A MX 2019009772A
Authority
MX
Mexico
Prior art keywords
lung cancer
antibodies
treatment
cancer
present
Prior art date
Application number
MX2019009772A
Other languages
English (en)
Inventor
Lowy Israel
RIETSCHEL Petra
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019009772A publication Critical patent/MX2019009772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar, reducir la gravedad o inhibir el crecimiento de cáncer (por ejemplo, cáncer de pulmón). Los métodos de la presente invención comprenden administrar una cantidad terapéuticamente efectiva de un antagonista de muerte programada 1 (PD-1) (por ejemplo, un anticuerpo anti-PD-1), a un sujeto con cáncer de pulmón en el que el tejido canceroso exprese PD-L1.
MX2019009772A 2017-02-21 2018-02-20 Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. MX2019009772A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461672P 2017-02-21 2017-02-21
US201762595190P 2017-12-06 2017-12-06
PCT/US2018/018747 WO2018156494A1 (en) 2017-02-21 2018-02-20 Anti-pd-1 antibodies for treatment of lung cancer

Publications (1)

Publication Number Publication Date
MX2019009772A true MX2019009772A (es) 2019-12-02

Family

ID=61628468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009772A MX2019009772A (es) 2017-02-21 2018-02-20 Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.

Country Status (11)

Country Link
US (3) US11292842B2 (es)
EP (1) EP3585812A1 (es)
JP (3) JP7324710B2 (es)
KR (2) KR20240011262A (es)
CN (2) CN110536905B (es)
AU (1) AU2018225102A1 (es)
CA (1) CA3054289A1 (es)
IL (2) IL268479B2 (es)
MA (1) MA47604A (es)
MX (1) MX2019009772A (es)
WO (1) WO2018156494A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY187739A (en) 2015-08-11 2021-10-18 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
KR20240011262A (ko) * 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
US20220177587A1 (en) 2018-09-19 2022-06-09 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
BR112021013887A2 (pt) * 2019-01-21 2021-09-21 Sanofi Rna terapêutico para cânceres de tumor sólido em estágio avançado
KR20210134690A (ko) * 2019-02-28 2021-11-10 리제너론 파아마슈티컬스, 인크. 피부 암을 치료하기 위한 pd-1 억제제의 투여
WO2021118321A1 (ko) * 2019-12-13 2021-06-17 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
BR112022018238A2 (pt) * 2020-03-13 2022-10-25 Univ Texas Método de tratamento de um câncer em um sujeito
WO2023185720A1 (zh) * 2022-03-28 2023-10-05 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2024077069A1 (en) * 2022-10-05 2024-04-11 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
RS54233B1 (en) 2008-08-25 2015-12-31 Amplimmune Inc. PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2013014668A1 (en) 2011-07-24 2013-01-31 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US9441045B2 (en) 2012-05-04 2016-09-13 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
US9889982B2 (en) 2012-07-23 2018-02-13 Silgan Dispensing Systems Corporation Aerosol actuators, devices, and methods of making and using the same
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2015030929A1 (en) 2013-08-30 2015-03-05 Ebay, Inc. Keyword bid optimization for text ads
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
CN110156893B (zh) 2013-12-17 2023-03-03 基因泰克公司 抗cd3抗体及使用方法
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR20170003692A (ko) * 2014-05-15 2017-01-09 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
KR102433464B1 (ko) 2014-05-28 2022-08-17 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
MX2016016903A (es) 2014-06-19 2017-03-27 Regeneron Pharma Animales no humanos que tienen un gen de muerte celular programada 1 humanizado.
SG11201703925VA (en) * 2014-12-02 2017-06-29 Celgene Corp Combination therapies
DK3254110T3 (da) 2015-02-03 2020-05-18 Ventana Med Syst Inc Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
BR112017019559B1 (pt) 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
KR20170138477A (ko) * 2015-04-17 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2016191751A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
CN108884164B (zh) 2016-02-25 2022-12-27 细胞医学瑞士公司 用于免疫疗法的经修饰细胞
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
KR20240011262A (ko) * 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation

Also Published As

Publication number Publication date
JP7384949B2 (ja) 2023-11-21
US11926668B2 (en) 2024-03-12
US20240209090A1 (en) 2024-06-27
IL308805A (en) 2024-01-01
IL268479A (en) 2019-09-26
JP2022078265A (ja) 2022-05-24
CN110536905A (zh) 2019-12-03
RU2019129506A (ru) 2021-03-23
US20200010550A1 (en) 2020-01-09
KR20190120792A (ko) 2019-10-24
CN117442719A (zh) 2024-01-26
WO2018156494A1 (en) 2018-08-30
EP3585812A1 (en) 2020-01-01
US20220281979A1 (en) 2022-09-08
IL268479B1 (en) 2024-02-01
JP2024016192A (ja) 2024-02-06
AU2018225102A1 (en) 2019-09-05
KR20240011262A (ko) 2024-01-25
JP2020508317A (ja) 2020-03-19
KR102628557B1 (ko) 2024-01-29
CA3054289A1 (en) 2018-08-30
JP7324710B2 (ja) 2023-08-10
MA47604A (fr) 2020-01-01
US11292842B2 (en) 2022-04-05
RU2019129506A3 (es) 2021-07-02
IL268479B2 (en) 2024-06-01
CN110536905B (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MY194085A (en) Methods of treating skin cancer by administering a pd-1 inhibitor
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2018007613A (es) Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
WO2016029073A3 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
MX2022004000A (es) Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon.
MX2018007756A (es) Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.
MY190324A (en) Anti-pd-1 antibodies and compositions
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
EP4279087A3 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
SG10201901057UA (en) Anti-pd-l1 antibodies
NZ729270A (en) Combination therapies with anti cd40 antibodies
NZ766356A (en) Anti-pd-1 antibodies
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA202090749A1 (ru) Способы совместной терапии для иммуномодуляции
PH12019500145A1 (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-á)
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
NZ728636A (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX2022002682A (es) Anticuerpos anti-cd73.
MX2020008569A (es) Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use